Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
42
2023 to 2026
Breakthrough
3
Accelerated
3
Priority review
11
Orphan
4
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 6 | 1 |
| 2024 | 6 | 3 |
| 2025 | 4 | 17 |
| 2026 | 4 | 1 |
42 approvals
Newest first. Hover a badge for what it means.
- Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc.Jul 7, 2026
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
- Utebzi (Tebipenem Pivoxil Hydrobromide) · GlaxosmithklineJun 17, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
- Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AGMay 29, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
- Epinephrine (Epinephrine) · Baxter Hlthcare CorpMar 30, 2026Original approval · NDA 220626Approval letter
- Flavalta (Epinephrine Bitartrate, Lidocaine Hydrochloride) · DeprocoMar 19, 2026Original approval · NDA 216564Approval letter
- Oziltus (Denosumab-Mobz) · Amneal Pharms LLCDec 19, 2025Original approval · BLA 761457Approval letter
- Boncresa (Denosumab-Mobz) · Amneal Pharms LLCDec 19, 2025Original approval · BLA 761456Approval letter
- Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc.Dec 12, 2025
To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise
- Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression
- Conexxence (Denosumab-Bnht) · Fresenius Kabi USA LLCOct 29, 2025Original approval · BLA 761398Approval letter
- Osenvelt (Denosumab-Bmwo) · Celltrion INCOct 29, 2025Original approval · BLA 761404Approval letter
- Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTDOct 29, 2025Original approval · BLA 761392Approval letter
- Aukelso (Denosumab-Kyqq) · Biocon Biologics INCOct 29, 2025Original approval · BLA 761436Approval letter
- Osvyrti (Denosumab-Desu) · Accord Biopharma Inc.Oct 29, 2025Original approval · BLA 761424Approval letter
- Enoby (Denosumab-Qbde) · Hikma Pharmaceuticals USA INCOct 29, 2025Original approval · BLA 761439Approval letter
- Bilprevda (Denosumab-Nxxp) · Shanghai Henlius BiotechOct 29, 2025Original approval · BLA 761444Approval letter
- Enoby (Denosumab-Qbde) · Hikma Pharmaceuticals USA INCSep 26, 2025Original approval · BLA 761439Approval letter
- Aukelso (Denosumab-Kyqq) · Biocon Biologics INCSep 16, 2025Original approval · BLA 761436Approval letter
- Bilprevda (Denosumab-Nxxp) · Shanghai Henlius BiotechAug 29, 2025Original approval · BLA 761444Approval letter
- Vanrafia (Atrasentan Hydrochloride) · NovartisApr 2, 2025
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
- Conexxence (Denosumab-Bnht) · Fresenius Kabi USA LLCMar 25, 2025Original approval · BLA 761398Approval letter
- Blujepa (Gepotidacin Mesylate) · GlaxosmithklineMar 25, 2025
To treat uncomplicated urinary tract infections
- Epinephrine (Epinephrine) · Fresenius Kabi USAMar 13, 2025Original approval · NDA 215425Approval letter
- Osenvelt (Denosumab-Bmwo) · Celltrion INCFeb 28, 2025Original approval · BLA 761404Approval letter
- Epinephrine Bitartrate In 0.9% Sodium Chloride (Epinephrine Bitartrate) · Baxter Hlthcare CorpFeb 28, 2025Original approval · NDA 218475Approval letter
- Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTDFeb 13, 2025Original approval · BLA 761392Approval letter
- Unloxcyt (Cosibelimab-Ipdl) · Checkpoint Therapeutics INCDec 13, 2024
To treat cutaneous squamous cell carcinoma
- Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
To treat classic congenital adrenal hyperplasia
- Orlynvah (Probenecid, Sulopenem Etzadroxil) · Iterum TherapOct 25, 2024
To treat uncomplicated urinary tract infections (uUTI)
- Neffy (Epinephrine) · Ars Pharms OperationAug 9, 2024Original approval · NDA 214697Approval letter
- Vigafyde (Vigabatrin) · Pyros PharmsJun 17, 2024
- Anktiva (Nogapendekin Alfa Inbakicept-Pmln) · Altor Bioscience, LLC, An Indirect Wholly-Owned SuApr 22, 2024
To treat bladder cancer
- Vafseo (Vadadustat) · AkebiaMar 27, 2024
To treat anemia due to chronic kidney disease
- Jubbonti (Denosumab-Bbdz) · Sandoz INCMar 5, 2024Original approval · BLA 761362Approval letter
- Exblifep (Cefepime Hydrochloride, Enmetazobactam) · Orchid PharmaFeb 22, 2024
To treat complicated urinary tract infections
- Defencath (Heparin Sodium, Taurolidine) · CormedixNov 15, 2023
To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter
- Rivfloza (Nedosiran Sodium) · NovoSep 29, 2023
To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function
- Posluma (Flotufolastat F-18 Gallium) · Blue EarthMay 25, 2023
To use with positron emission tomography imaging in certain patients with prostate cancer
- Elfabrio (Pegunigalsidase Alfa-Iwxj) · Chiesi Farmaceutici SpaMay 9, 2023
To treat confirmed Fabry disease
- Adrenalin (Epinephrine) · Ph HealthApr 21, 2023Original approval · NDA 215875Approval letter
- Filspari (Sparsentan) · TravereFeb 17, 2023
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
- Jesduvroq (Daprodustat) · GlaxosmithklineFeb 1, 2023
To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.